The SynCardia temporary total artificial heart provides a full heart replacement option in biventricular failure patients without the need for immunosuppression.
Total artificial hearts are evolving as a bridge-to-transplantation and potential long-term alternative for patients with end-stage biventricular failure.
Absolute Event Rate: 0% vs 0%
TAH offers full heart replacement and is evolving toward becoming a long-term alternative to transplants. Challenges like power supply, long-term durability, and biocompatibility are being addressed through innovations such as fully implantable systems and hybrid biological-mechanical designs. Unlike transplantation, TAHs avoid immunosuppression and offer hope to patients who cannot wait for donor hearts.In the coming years, global development of advanced TAHs, coupled with better clinical acceptance could transform treatment of end-stage heart failure providing a more accessible, reliable, and life-sustaining solution.
Rubin et al. (Tue,) reported a other. The SynCardia temporary total artificial heart provides a full heart replacement option in biventricular failure patients without the need for immunosuppression.